Newsletter | September 19, 2023

09.19.23 -- Protein Degraders: Progress, Limitations, & Future Directions

FEATURED EDITORIAL

Protein Degraders: Progress, Limitations, And Future Directions

By Weijun Gui and Thomas Kodadek, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology

There is great excitement surrounding the development of small molecules that trigger the degradation of proteins. This article will highlight proteolysis targeting chimeras (PROTACs), their current limitations, and the emerging strategies to address those limitations, resulting in a bright future for targeted protein degradation.

FDA Finalizes Guidance On Nonclinical Evaluation Of Pharmaceutical Immunotoxicity

By Tim Sandle, Ph.D.

The FDA has now finalized a guidance document on the immunotoxic potential of pharmaceuticals. The FDA builds on current ICH guidance and proposes a two-stage approach. Central to the guidance is using a risk framework.

INDUSTRY INSIGHTS

Prioritize Solvent Recycling And Recovery To Realize Your Green Goals

Article | By Niklaus Künzle and Brian Schwegler, Lonza

Building more sustainable practices across the pharmaceutical industry takes a collaborative and transparent effort. One leading CDMO is leveraging their solvent recovery efforts to yield major strides.

Design Of Experiments Approach To Enabling Studies For Process Validation

Article | By Matthew Schiesher, Ph.D., Cambrex

A recent project applied process improvement methodology to the process validation step that ultimately provided not only an optimized, robust process but also an economic advantage.

Unexpected SEC Results: Can They Be Improved?

Q&A | By Jon Lundqvist, Cytiva

Sometimes, your size exclusion chromatography (SEC) results don’t look the way you want them to. Learn how to fix issues such as poor resolution, peak tailing, and fronting from the tips shared in this FAQ.

Nanoscale Technology's Potential: A Fireside Chat With Industry Leaders

Webinar | Nanoform

Nanoform CEO Edward Haeggstrom, and Shawn Davies, head of drug delivery, biopharmaceuticals development, AstraZeneca, discuss the potential of nanoscale medicines and delivery devices.

Challenges Associated With In-Use Simulated Administration Of Biologics

Webinar | Lonza

Explore some of the more challenging aspects surrounding in-use testing for parenteral delivery, along with potential strategies to address these issues.

MOST POPULAR NEWS

•

Researchers Discover Genes Behind Antibiotic Resistance In Deadly Superbug Infections

•

Zuberitamab Has Been Approved For Marketing In China

•

Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration

•

Biosyngen Received FDA Approval For Phase I/II Clinical Trials For BRL03

•

CyGenica Limited Secures USFDA Approval For ODD For Novel Drug Conjugate In GBM Treatment

•